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Abstract: Introduction: Although hypovolemia remains the most relevant problem during acute de-
compensated diabetes in its clinical manifestations (diabetic ketoacidosis, DKA, and hyperglycemic 
hyperosmolar state, HHS), the electrolyte derangements caused by the global hydroelectrolytic imbal-
ance usually complicate the clinical picture at presentation and may be worsened by the treatment it-
self. 
Aim: This review article is focused on the management of dysnatremias during hyperglycemic hy-
perosmolar state with the aim of providing clinicians a useful tool to early identify the sodium de-
rangement in order to address properly its treatment. 
Discussion: The plasma sodium concentration is modified by most of the therapeutic measures com-
monly required in such patients and the physician needs to consider these interactions when treating 
HHS. Moreover, an improper management of plasma sodium concentration (PNa
+
) and plasma osmo-
lality during treatment has been associated with two rare potentially life-threatening complications 
(cerebral edema and osmotic demyelination syndrome). Identifying the correct composition of the flu-
ids that need to be infused to restore volume losses is crucial to prevent complications. 
Conclusion: A quantitative approach based on the comparison between the measured PNa+ (PNa+M) 
and the PNa
+
 expected in the presence of an exclusive water shift (PNa
+
G) may provide more thorough 
information about the true hydroelectrolytic status of the patient and may therefore, guide the physician 
in the initial management of HHS. On the basis of data derived from our previous studies, we propose 
a 7-step algorithm to compute an accurate estimate of PNa
+
G. 
Keywords: Hyperglycemic hyperosmolar state, hyponatremia, hypernatremia, cerebral edema, osmotic demyelination syn-
drome, fluid therapy. 
1. INTRODUCTION 
Hypovolemia is one of the most relevant clinical prob-
lems during acutely decompensated diabetes mellitus, irre-
spective of whether it is Diabetic Ketoacidosis (DKA) or Hy-
perglycemic Hyperosmolar State (HHS). Moreover, different 
electrolyte derangements may coexist with hypovolemia at 
the onset or may be caused by fluid replacement itself, if the 
composition of the infused saline solution is not appropriate. 
Therefore, a careful evaluation of plasma osmolality 
(POsm), sodium (PNa
+
) and potassium concentrations (PK
+
) 
and of acid-base status is crucial to determine the correct 
composition of fluids to be administered. 
This review is focused on the management of PNa
+
 dur-
ing HHS. Particularly, we will discuss the potential role of a  
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quantitative approach to dysnatremias in identifying the 
proper amount of Na
+
 and K
+
 that need to be infused in order 
to prevent harmful derangements in POsm as well as two 
associated life-threatening complications: cerebral edema 
and Osmotic Demyelination Syndrome (ODS). 
2. PATHOPHYSIOLOGY 
In HHS the Extracellular Volume (ECV) effective osmo-
lality (tonicity) is increased due to the elevation in the 
plasma glucose concentration (PG) according to the follow-
ing formula: 
Effective osmolality (mOsm/kgH2O)  2  PNa
+
 
(mmol/L) 2PK
+
 (mmol/L)PG (mg/dL) / 18
Blood urea nitrogen is not included in this particular for-
mula since it does not affect the osmotic gradient across cell 
membranes, being permeable through them [1, 2]. 
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The restriction of glucose to the ECV generates an os-
motic gradient which shifts water from the Intracellular Vol-
ume (ICV) to the ECV, leading to a dilutional fall in PNa
+
 
[3]. In the absence of preexisting or associated electrolyte 
derangements, this process causes hypertonic hyponatremia 
since, despite a low PNa
+
, POsm rises, usually above 320 
mOsm/kg due to the high PG. 
Obviously, this is not a static condition and other vari-
ables affect the process. 
First of all, hyperglycemia causes an osmotic diuresis 
which increases renal excretion of water in excess of that of 
Na
+
 and other ions. This large electrolyte-free water output 
tends to raise both PNa
+
 and POsm [4-6]. Water intake is 
consequently one of the main determinants of the clinical 
presentation and the laboratory findings of hyperglycemic 
crisis: in fact, in those patients who are able to compensate 
the volume lost through osmotic diuresis with oral water 
intake, the rise in POsm can be dampened, while PNa
+
 tends 
to be even lower. On the contrary, as HHS usually develops 
in elderly patients with an impaired thirst mechanism 
and/or a reduced access to water [7], volume depletion is 
often prevailing, such that the measured PNa
+
 can be nor-
mal or even increased (averaging 149 mEq/L in some stud-
ies [2, 8]). 
A further crucial issue is K
+
 replacement. In the first 
phases of treatment, a high infusion rate of K
+
 salts may be 
required to prevent insulin-induced hypokalemia (even up to 
10-20 mmol/h [9]). However, K
+
 administration leads to a 
rise in PNa
+
, since all millimoles of K
+
 infused should be 
considered as molar Na
+
 equivalents; this means that K
+
 ad-
ministration induces an increase in PNa
+
 comparable to that 
observed when the same amount of Na
+
 is infused [10, 11]. 
Therefore, the amount of K
+
 administered has to be carefully 
considered during fluid infusion in order to avoid an overly 
rapid correction of hyponatremia or even the onset of hyper-
natremia [12]. 
The process is further enhanced by the simultaneous ad-
ministration of insulin that promotes K
+
 entry into cells in 
several tissues (mainly liver, skeletal muscle, cardiac muscle 
and adipose tissue) [13, 14]. This effect is mediated by many 
transport pathways, particularly by the Na
+
/K
+
 ATPase [15], 
which pumps Na
+
 out of the ICV in exchange for K
+
, thus 
contributing to the increase in PNa
+
. 
Other important elements that should be taken into ac-
count during fluid replacement are vomiting and nasogastric 
suction, which can increase water, solute and hydrogen ion 
losses. 
3. QUANTITATIVE APPROACH 
Over the years many correction factors have been pro-
posed in order to help the physician to calculate PNa
+
 ex-
pected in the presence of hyperglycemia. 
Until 1973, clinicians estimated a fall in PNa
+
 of 2.8 
mmol/L for every 100 mg/dL increase in PG that occurred 
above a concentration of 100 mg/dL [16]. In 1973 Katz sug-
gested that the water shift should stop before the normal 
ECV osmolality is restored, thus producing hyperosmolality 
in both compartments; on this basis, he mathematically cal-
culated a correction factor of 1.6 mmol/L [17]. Later, in 
1999, Hillier et al. demonstrated that the higher is PG, the 
more inaccurate is the correction factor proposed by Katz; a 
correction factor of 2.4 mmol/L was then introduced in clini-
cal practice, although the Authors themselves admitted that it 
still underestimates the reduction in PNa
+
 for PG400 mg/dL 
and that, above this cut-off, a correction factor of 4 mmol/L 
is more reliable [18]. 
Although in the following years, a large number of stud-
ies have analyzed and reviewed the proposed correction fac-
tors [19], even now there is no consensus on which one 
should be considered the most accurate: for example, the 
American Diabetes Association (ADA) guidelines for the 
treatment of DKA and HHS [9] report the one proposed by 
Katz and then re-evaluated by Nguyen et al. (1.6 mmol/L) 
[20], while Spasovski et al. report in their clinical guidelines 
for the treatment of hyponatremia the value suggested by 
Hillier et al. (2.4 mmol/L) [21]. 
However, although the Literature seems deeply focused 
on this essentially mathematical aspect, it is important to 
highlight that the PNa
+
/PG ratio is affected by many vari-
ables that cannot be included in the simplified equations pro-
posed, such that this ratio can widely vary depending on the 
magnitude of the concomitant solute and/or water depletion. 
We already demonstrated this effects in previous works 
using a computer simulation model [22-24]. 
Another challenging issue is the estimate of volume 
status; although these patients are almost always dehy-
drated, an accurate estimate of volume status is very impor-
tant in order to avoid adverse events related to an incorrect 
treatment. Excluding invasive techniques (such as 
transpulmonary thermodilution [25]), that are not applica-
ble to this kind of patients, non-invasive methods (based on 
echocardiography [26], changes in the pulse oximeter 
waveform [27] or biomarkers as copeptin [28]), although 
effective in identifying fluid overload, are not widely avail-
able and, at the moment, give unreliable results from the 
quantitative point of view. For these reasons we based our 
model on anthropometric measurements; we previously set 
up a mathematical model that allowed us to estimate both 
the ECV and the glucose excess [29]. We then computed 
the PNa
+
 expected on the basis of the water shift caused by 
hyperosmolality (PNa
+
G). The difference between the PNa
+
G 
and the measured PNa
+
 (PNa
+
M) stratified patients into 3 
groups: 
• PNa
+
MPNa
+
G: in this situation, the measured PNa
+
 is 
comparable to that predicted by the water shift; this 
means that no changes in either water or Na
+
 content 
occurred, and that hyponatremia is completely ex-
plained by the dilution of Na
+
 content caused by wa-
ter flows across cell membranes; 
• PNa
+
MPNa
+
G: in this situation the measured PNa
+
 is 
lower than the expected one; it means that Na
+
 deficit 
is greater than water losses; 
• PNa
+
M PNa
+
G: in this situation the measured PNa
+
 is 
higher than the expected one; it means that either an 
absolute water deficit is present or that it prevails 
over the associated Na
+
 loss.  
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This classification is useful in clinical practice and helps 
the physician to choose the correct initial fluid treatment.  
4. TREATMENT 
The first goal in treating HHS is to restore the water defi-
cit, which averages 100-200 mL/kg (about 10.5 L in a typical 
70-kg man) because of the massive losses due to the osmotic 
diuresis [30]. Water deficit is usually larger in HHS com-
pared to DKA. In fact, while the relative lack of insulin al-
lows the development of higher PG during the longer time 
course, the total lack of insulin in type 1 diabetes mellitus 
leads to earlier ion and acid-base derangements (euglycemic 
DKA also exists [31]) that call for earlier attention, as they 
are invariably fatal if left untreated. Fluid treatment is meant 
to expand the circulating volume, thus improving renal per-
fusion and function. It has been also demonstrated that this 
reduces the counter-regulatory hormone release and insulin 
resistance [32]. As already stated, selecting the proper fluid 
to be infused is important to avoid treatment complications. 
Isotonic saline (0.9% NaCl) is usually suggested as the first 
choice in emergency conditions: it is recommended to ad-
minister 1000-1500 mL in the first hour and then to reduce 
the infusion rate according to the hemodynamic and clinical 
response [9, 33]. Infusion rates should always be made com-
patible with the patients’ cardiac function, although the 
overall water deficit should be corrected within the first 24 
hours of treatment [9]. However, as soon as hemodynamic 
stability has been achieved, it is important to switch to other 
solutions according to the corrected PNa
+
 (PNa
+
G) with the 
aim to avoid treatment-related dysnatremias. The classifica-
tion we previously presented [22] can reasonably guide this 
choice: 
• If PNa
+
M  PNa
+
G, isotonic saline is the appropriate 
choice in order to compensate the Na
+
 deficit due to 
osmotic diuresis; 
• If PNa
+
M PNa
+
G, a hypotonic fluid should be given in 
order to simultaneously administer a larger amount of 
water coupled to a lower amount of Na
+
, avoiding to 
worsen or to generate hypernatremia; 
• If PNa
+
M  PNa
+
G, both 0.9% and 0.45% NaCl solu-
tions can be appropriated, and their relative amounts 
are usually determined by the consideration that PNa
+
 
will gradually rise along with insulin treatment (since 
the glucose shift from the ECV to the ICV reverses 
the osmotic gradient and drags water to the ICV, thus 
concentrating the ECV Na
+
 content). 
As already stated, the molar equivalence existing be-
tween Na
+
 and K
+
 implies that 1 millimole of KCl will raise 
the PNa
+
 exactly as 1 mmol of NaCl will. Therefore, the need 
to give supplemental K
+
 together with fluid replacement 
must be considered in choosing the adequate solution. For 
example, in the last case presented above (PNa
+
M  PNa
+
G), if 
K
+
 supplementation is required, hypotonic fluids should be 
preferred in order to avoid an overly rapid or even excessive 
increase in PNa
+
 and its associated risks. Particularly, ADA 
recommends to administer supplemental K
+
 when: 
• PK
+
3.3 mmol/L before insulin infusion is started; 
• 3.3	P


 5.2 mmol/L during insulin infusion. 
K
+
 supplementation is not safe, and often unnecessary, 
when PK
+
5.2 mmol/L, but PK
+
 has to be closely monitored 
(usually every 2 hours) during continuous insulin infusion 
[9]. As already described, this latter recommendation is ex-
plained by the K
+
 transport into cells promoted by the hor-
mone, mainly through the activation of Na
+
/K
+
 ATPase [15]. 
Because of the constriction imposed by electrical neutrality, 
this molecular mechanism requires that Na
+
 shifts from cells 
to interstitium, such that a further rise in PNa
+
 must be ex-
pected. 
On the other hand, it is important to be aware that the in-
fusion of hypotonic solutions becomes necessary when PG 
falls below 300 mg/dL: in fact, glucose supplementation is 
required in order to keep PG within the 200-300 mg/dL 
range, so that glycogen stores can be gradually rebuilt [9]. 
The administration of such a large amount of electrolyte-free 
water has the obvious consequence to dampen the rise in 
PNa
+
 related to previous and simultaneous treatments (saline, 
insulin infusions, K
+
 supplementation). 
Because of a large number of variables that affect the 
PNa
+
 variation in time (related both to the above mentioned 
treatments and to free water renal excretion), it is recom-
mended to check electrolytes (together with venous pH, glu-
cose and creatinine) at least every 2-4 hours in order to guide 
therapy [9]. 
To guide treatment, Table 1 reports the composition of 
the most common solutions available in clinical practice, 
including Ringer’s and glucose solutions.  
4.1. Treatment Complications 
It has been demonstrated that brain cells are partially 
permeable to glucose regardless of insulin action because of 
a selective expression of transport proteins [34]. Therefore, 
hypertonicity exclusively due to hyperglycemia is physio-
logically dampened in the Central Nervous System (CNS). 
On the other hand, hypertonicity due to hypernatremia has a 
greater impact on the CNS and it has been suggested that the 
PNa
+
 is a better predictor of neurological impairment than the 
PG itself, since severely hyperglycemic patients can be fully 
asymptomatic in the absence of hypernatremia [35]. 
However, when the development of hypernatremia-
related hypertonicity is gradual, brain cells can activate an 
adaptation mechanism based on the accumulation of both 
inorganic osmolytes (basically electrolytes) and organic os-
molytes (the so-called idiogenic osmoles) in order to reduce 
the osmotic transmembrane gradient, preventing an exces-
sive water shift from cells and the related brain shrinking 
[36]. 
Treatment-related complications occur when these 
pathophysiological processes are ignored. 
Clinically apparent cerebral edema causes a symptoma-
tology characterized by headache, insisted vomiting, sei-
zures, papilledema, abnormal pupillary response, cranial 
nerves palsies, altered mental status and impaired conscious-
ness, sphincter incontinence, rising blood pressure with in-
appropriate bradycardia up to respiratory arrest [37-39]. 
Overt cerebral edema is uncommon in HHS and in adults 
[40], predominantly occurring in children with DKA (0.3-
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1.0% of DKA episodes in children [41], with a 21-24% mor-
tality rate [42]). However, studies involving computerized 
tomography, electroencephalography and magnetic reso-
nance diffusion-weighted imaging have demonstrated that 
the development of subclinical cerebral edema is frequent 
during the first 24 hours of treatment of hyperglycemic 
emergencies [4, 43-45]. The most accredited theory claims 
that cerebral edema is caused by an overly rapid reduction in 
POsm [46]: brain cells, which previously adapted to hyper-
tonicity by accumulating idiogenic osmoles, become hyper-
tonic when the POsm falls, because the elimination of or-
ganic osmolytes is a slow process compared to the quick 
changes in PG during treatment [4]: thus, the reverse osmotic 
gradient generates a water shift into brain cells. However, 
new evidences from recent clinical studies question the piv-
otal importance of this mechanism, as the pathogenesis of 
cerebral edema during hyperglycemic emergencies seems to 
be vasogenic rather than cytotoxic [47]: in fact, different 
rehydration protocols were not related to different rates of 
subclinical cerebral edema in a randomized clinical trial [48]. 
These findings may prove the role of other less reputed 
mechanisms, such as hypoxia, ischemia/reperfusion-like 
injury, inflammation and impaired ion transport [9]. Any-
way, the only measure suggested to prevent cerebral edema 
in such patients is still a gradual reduction of POsm, that 
should be obtained by avoiding an excessive rehydration, by 
gradually decreasing the PG (the recommended rate is 50-75 
mg/dL/h) and then by using glucose infusions to keep the PG 
within a 200-300 mg/dL range as long as the POsm is being 
normalized and the patient remains mentally alert [9].  
ODS is a life-threatening complication typically associ-
ated with the overly rapid correction of a hypotonic state 
(typically, chronic hyponatremia) [49]. The clinical syn-
drome, characterized by the development of neurological 
impairment (confusion, drowsiness, altered mental status up 
to respiratory arrest or a so-called locked-in syndrome) even 
a few days after the correction of the hypotonic condition, is 
produced by an acute shrinking in brain cells with a secon-
dary blood-brain barrier damage which triggers an inflamma-
tory response, mainly complement-mediated [50]. This phe-
nomenon, which is pathophysiologically related to adapta-
tion mechanisms to hypotonicity, is more likely to occur in 
encephalic areas where cells are less prone to eliminate 
idiogenic osmoles, such as the central part of basal pons 
(central pontine myelinolysis) [51]. ODS is not typically 
associated to HHS: only a few case reports have been pub-
lished since 1989, some of them reporting the neurological 
impairment at presentation (suggesting a possible role of 
hyperglycemia in the development of brain damage [52]), 
others as a complication of treatment [53]. Pathophysiologi-
cally, an overly rapid correction of Na
+
 deficit (in those with 
PNa
+
M  PNa
+
G) or a further increase in the PNa
+
 (in those 
with PNa
+
MPNa
+
G or PNa
+
MPNa
+
G) can cause rapid fluc-
tuations in POsm, essentially identical to the conditions that 
produce ODS while treating hyponatremia [54]. This com-
plication explains why it is so important to evaluate the Na
+
 
content of the infused fluids and to consider the effect of K
+
 
and insulin on the PNa
+
. The occurrence of a catastrophic 
ODS when treating HHS remains infrequent, but an overly 
rapid development of iatrogenic hypernatremia may still 
worsen the patient’s neurological status and must be 
avoided. 
5. EXAMPLES 
Figs. (1 and 2) give a schematic representation of the 
changes produced by hyperglycemia in total body water 
(TBW), ICV, ECV and their respective concentrations of 
Na
+
, Cl
-
, other (than chloride) anions (OAN) and osmolality. 
The same starting condition (A), modified by the same glu-
cose addition, can evolve towards different clinical features 
according to different adaptive responses. Fig. (1) exempli-
fies the two extreme clinical patterns: 
• In B (the typical HHS presentation) osmotic diuresis 
produces massive water losses, which are larger than 
solute losses and are not completely compensated by 
water intake, thus producing a higher PG, a higher 
POsm and either normonatremia or hypernatremia; 
• In C free water intake is higher (mainly because thirst 
and consciousness are preserved) and the effects of the 
osmotic diuresis are partially compensated, thus pro-
ducing a lower water deficit, a proportionally higher 
Table 1. Composition of the most common solutions available in clinical practice. 
Solution 
Na
+
 
(mEq/L) 
K
+
 
(mEq/L) 
Cl
-
 
(mEq/L) 
Glucose 
(g/L / mM) 
Osmolarity (mOsm/L) pH 
0.9% NaCl (Normal saline) 154 0 154 0 308 5 
0.45% NaCl ( Normal saline) 77 0 77 0 154 5 
0.22% NaCl ( Normal saline) 39 0 39 0 78 5 
Ringer’s solutions * 130 4 109 0 273 6.5 
5% Glucose in water † 0 0 0 50 / 278    278 † 5 
10% Glucose in water † 0 0 0 100 / 556    556 † 5 
5% Glucose in 0.45% NaCl † 77 0 77 50 / 278    406 † 5 
*The table reports the typical composition of Ringer’s solutions, but the content of each component may slightly vary among different producers. 
†Since glucose is rapidly absorbed into the cells as a result of insulin action, the solutions of glucose in water can be considered hypotonic (although 5% is actually isotonic and 10% 
hypertonic); similarly, the final tonicity of the solutions of glucose in saline depends on the sodium chloride concentration (usually 0.45%). 
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solute loss and, consequently, a lower PG, a lower 
POsm and either hyponatremia or normonatremia. 
 
Fig. (1). The same baseline condition (A), modified by the same 
amount of GA (600 mmol) can evolve towards two opposite clinical 
presentation depending on whether or not the patient compensate 
osmotic diuresis with water intake (respectively B and C). 
46 mmol/L = 830 mg/dL; 42 mmol/L = 758 mg/dL. 
 
 Fig. (1) reports two extreme examples in which the 
proper fluid to be infused would be easy to identify. How-
ever, in less striking cases, the correct choice may not be 
clearly evident. Therefore, once hemodynamic stability is 
ensured, it is mandatory to obtain information about the pa-
tient’s volume status through the physical examination 
(blood pressure, heart rate and their orthostatic changes; skin 
and mucous hydration, jugular or peripheral veins distension 
or collapse); additionally, body weight and its recent changes 
may give valuable information, but these data are hardly ever 
available, especially in the Emergency Department. 
Laboratory tests needed to set the proper treatment in-
clude POsm, PG, PNa
+
, PK
+
 and PCl
-
. These data allow the 
clinician to compute the amount of water and cations to be 
administered in order to restore volume deficit and correct 
electrolyte derangements. The formulas we propose (re-
ported in Table 2) are taken from our previous work, where 
the boundary conditions for their applicability were also 
identified: POsm1280 mOsm/L (a necessary requirement in 
HHS) and PCl1/PNa10.75 [24]. 
 
Table 2. Step-by-step algorithm to calculate PNa
+
G. The re-
quired variables are POsm0 and POsm1, normal body 
weight (needed to compute TBW0 and then ECV0), 
PNa
+
0, PNa
+
1 and PG1. 
-  Step-by-step Algorithm to Compute PNa
+
G 
1. Compute the first 
estimate of the varia-
tion in total body 
water  
VFE  (POsm  TBW0) / POsm1 
2. Compute the first 
estimate of the varia-
tion in Na+ content 
Na+FE  (PNa+1  PNa+0)  VFE 
3. Compute the final 
extracellular volume 
ECV1  [(PNa+0  ECV0) – Na+FE] / PNa+1 
4. Compute the amount 
of glucose in ex-
tracellular volume 
GA  PG1  ECV1 
5. Compute the pOsmG 
(rise in POsm exclu-
sively due to GA) 
POsmG  [(POsm0  TBW0)  GA] / TBW0 
6. Compute the ex-
tracellular volume 
expected in the pres-
ence of exclusive 
osmotic water shift 
ECVG  TBW0 – [(POsm0  ICV0) / POsmG] 
7. Compute the PNa
+ 
expected in the pres-
ence of exclusive 
osmotic water shift 
PNa+G  (PNa+0  ECV0) / ECVG 
 
 Fig. (2) presents laboratory data from four hypothetical 
example patients along with the respective computed PNa
+
G. 
We think that these formulas can represent a valuable 
tool for the physician when fluids treatment of HHS needs 
GA = +600 mmol
NaCl = -110 mEq
NaHCO3 = -10 mEq
ΔV = -7 L
GA = +600 mmol
NaCl = -280 mEq
NaHCO3 = -20 mEq
ΔV = -2 L
PNa
+ = 152 mEq/L
PCl
- = 112 mEq/L
POAN = 40 mEq/L
 
POsm = 350 mOsm/L
 
 
PG = 46 mmol/L
 
 
 
 
ICOsm = 350 mOsm/L
 
 
ICG = 0 mmol/L
TBW = 33 L
ECV = 13 L ICV = 20 L
B 
PNa
+ = 126 mEq/L
PCl
- = 91 mEq/L
POAN = 35 mEq/L
 
POsm = 295 mOsm/L
 
 
PG = 42 mmol/L
 
 
 
 
ICOsm = 295 mOsm/L
 
 
ICG = 0 mmol/L
TBW = 38 L
ECV = 14.2 L ICV = 23.8 L
C 
PNa
+ = 140 mEq/L
PCl
- = 105 mEq/L
POAN = 35 mEq/L
 
 
POsm = 280 mOsm/L
 
 
 
 
 
ICOsm = 280 mOsm/L
ECV = 15 L ICV = 25 L
A 
TBW = 40 L
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to be started. However, since the computing algorithm in-
cludes different steps with a number of variables, in order 
to simplify its use in clinical practice, we are setting up an 
easily available calculation tool that instantly provides the 
PNa
+
G and other data that, together with a careful clinical 
examination, help the physician to choose the correct 
treatment. 
CONCLUSION 
Although hypovolemia remains the most relevant prob-
lem in HHS and requires immediate correction, electrolyte 
derangements and particularly dysnatremias usually compli-
cate and worsen the global clinical picture. Most of the 
therapeutic measures routinely necessary in HHS (fluids 
infusion, insulin infusion, K
+
 supplementation) affect PNa
+
. 
The physician needs to be aware of this as well as of the un-
derlying pathophysiological mechanisms in order to predict 
the change in PNa
+
 and prevent the potential complications 
of improper treatments. The quantitative approach we pro-
pose on the basis of our previous works can provide more 
accurate information about the patient’s hydroelectrolytic 
status and guide the physician in the choice of the proper 
 
Fig. (2). The same baseline condition (A), modified by different combinations of GA, Na
+
 lost and volume lost, can produce different clinical 
presentations. The ratio between PNa
+
G and PNa
+
M can help the physician to estimate whether volume losses prevail over Na
+
 losses (D), Na
+
 
losses prevail over volume losses (G) or the two actually balance and the reduction in PNa
+
 can be approximated to that exclusively produced 
by water shift (E, F). PNa
+
G has been calculated with the formulas reported in Table 2. 
30 mmol/L = 543 mg/dL; 22 mmol/L = 388 mg/dL; 46 mmol/L = 830 mg/dL; 47 mmol/L = 849 mg/dL. 
PNa
+ = 140 mEq/L
PCl
- = 105 mEq/L
POAN = 35 mEq/L
 
 
POsm = 280 mOsm/L
 
 
 
 
 
ICOsm = 280 mOsm/L
ECV = 15 L ICV = 25 L
A 
TBW = 40 L
GA = +400 mmol
NaCl = -250 mEq
NaHCO3 = -10 mEq
ΔV = -4 L
GA = +700 mmol
NaCl = -280 mEq
NaHCO3 = -20 mEq
ΔV = -1 L
GA = +300 mmol
NaCl = -210 mEq
NaHCO3 = -20 mEq
ΔV = -2 L
GA = +600 mmol
NaCl = -350 mEq
NaHCO3 = -30 mEq
ΔV = -4 L
PNa
+
M = 139 mEq/L
> 
PNa
+
G = 132 mEq/L
ECV = 13.3 L ICV = 22.7 L
PNa
+ = 139 mEq/L
PCl
- = 100 mEq/L
POAN = 39 mEq/L
 
POsm = 308 mOsm/L
 
 
PG = 30 mmol/L
 
 
 
 
ICOsm = 308 mOsm/L
 
 
ICG = 0 mmol/L
TBW = 36 L
D 
PNa
+ = 121 mEq/L
PCl
- = 87 mEq/L
POAN = 34 mEq/L
 
POsm = 290 mOsm/L
 
 
PG = 47 mmol/L
 
 
 
 
ICOsm = 290 mOsm/L
 
 
ICG = 0 mmol/L
TBW = 39 L
ECV = 14.8 L ICV = 24.2 L
G 
PNa
+
M = 121 mEq/L
< 
PNa
+
G = 127 mEq/L
PNa
+
M = 134 mEq/L
≈ 
PNa
+
G = 134 mEq/L
PNa
+ = 134 mEq/L
PCl
- = 98 mEq/L
POAN = 36 mEq/L
 
POsm = 291 mOsm/L
 
 
PG = 22 mmol/L
 
 
 
 
ICOsm = 291 mOsm/L
 
 
ICG = 0 mmol/L
TBW = 38 L
ECV = 13.9 L ICV = 24.1 L
E 
PNa
+
M = 130 mEq/L
≈ 
PNa
+
G = 129 mEq/L
PNa
+ = 130 mEq/L
PCl
- = 92 mEq/L
POAN = 38 mEq/L
 
POsm = 307 mOsm/L
 
 
PG = 46 mmol/L
 
 
 
 
ICOsm = 307 mOsm/L
 
 
ICG = 0 mmol/L
TBW = 36 L
ECV = 13.2 L ICV = 22.8 L
F 
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composition of the fluids that need to be infused to restore 
volume losses. 
LIST OF ABBREVIATIONS  
DKA = Diabetic Ketoacidosis 
HHS = Hyperglycemic Hyperosmolar State 
POsm = Plasma Osmolality 
PNa
+
 = Plasma Sodium Concentration 
PK
+
 = Plasma Potassium Concentration 
ODS = Osmotic Demyelination Syndrome 
ECV = Extracellular Volume 
PG = Plasma Glucose Concentration 
ICV = Intracellular Volume 
PNa
+
G = Plasma Sodium Concentration Expected in 
the Presence of Exclusive Osmotic Water 
Shift 
PNa
+
M = Measured Plasma Sodium Concentration 
CNS = Central Nervous System 
TBW = Total Body Water 
PCl
-
 = Plasma Chloride Concentration 
POAN = Plasma Concentration of Anions other than 
Chloride 
GA = Amount of Glucose in Extracellular Vol-
ume 
VFE = First Estimate of the Variation in Total 
Body Water 
Na
+
FE = First Estimate of the Variation in Na
+
 Con-
tent 
pOsmG = Rise in Plasma Osmolality Exclusively 
Due to the Amount of Glucose Diluted in 
Extracellular Volume 
ECVG = Extracellular Volume Expected in the 
Presence of Exclusive Osmotic Water Shift 
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